Functional differences between E. Coli and eskape pathogen groes/groel
Author
Sivinski, J.Ambrose, A.J.
Panfilenko, I.
Zerio, C.J.
Machulis, J.M.
Mollasalehi, N.
Kaneko, L.K.
Stevens, M.
Ray, A.-M.
Park, Y.
Wu, C.
Hoang, Q.Q.
Johnson, S.M.
Chapman, E.
Affiliation
Department of Pharmacology and Toxicology, College of Pharmacy, University of ArizonaDepartment of Chemistry and Biochemistry, University of Arizona
Issue Date
2021
Metadata
Show full item recordPublisher
American Society for MicrobiologyCitation
Sivinski J, Ambrose AJ, Panfilenko I, Zerio CJ, Machulis JM, Mollasalehi N, Kaneko LK, Stevens M, Ray A-M, Park Y, Wu C, Hoang QQ, Johnson SM, Chapman E. 2021. Functional differences between E. coli and ESKAPE pathogen GroES/GroEL. mBio 12:e02167-20.Journal
mBioRights
Copyright © 2021 Sivinski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
As the GroES/GroEL chaperonin system is the only bacterial chaperone that is essential under all conditions, we have been interested in the development of GroES/GroEL inhibitors as potential antibiotics. Using Escherichia coli GroES/GroEL as a surrogate, we have discovered several classes of GroES/GroEL inhibitors that show potent antibacterial activity against both Gram-positive and Gram-negative bacteria. However, it remains unknown if E. coli GroES/GroEL is functionally identical to other GroES/GroEL chaperonins and hence if our inhibitors will function against other chap-eronins. Herein we report our initial efforts to characterize the GroES/GroEL chapero-nins from clinically significant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). We used complementation experiments in GroES/GroEL-deficient and-null E. coli strains to report on exogenous ESKAPE chaperone function. In GroES/ GroEL-deficient (but not knocked-out) E. coli, we found that only a subset of the ESKAPE GroES/GroEL chaperone systems could complement to produce a viable orga-nism. Surprisingly, GroES/GroEL chaperone systems from two of the ESKAPE pathogens were found to complement in E. coli, but only in the strict absence of either E. coli GroEL (P. aeruginosa) orbothE. coli GroES and GroEL (E. faecium). In addition, GroES/ GroEL from S. aureus was unable to complement E. coli GroES/GroEL under all condi-tions. The resulting viable strains, in which E. coli groESL was replaced with ESKAPE groESL, demonstrated similar growth kinetics to wild-type E. coli, butdisplayedan elongated phenotype (potentially indicating compromised GroEL function) at some temperatures. These results suggest functional differences between GroES/GroEL chaperonins despite high conservation of amino acid identity. IMPORTANCE The GroES/GroEL chaperonin from E. coli has long served as the model system for other chaperonins. This assumption seemed valid because of the high conservation between the chaperonins. It was, therefore, shocking to discover ESKAPE pathogen GroES/GroEL formed mixed-complex chaperonins in the presence of E. coli GroES/GroEL, leading to loss of organism viability in some cases. Complete replacement of E. coli groESL with ESKAPE groESL restored organism viability, but produced an elongated phenotype, suggesting differences in chaperonin function, including client specificity and/or refolding cycle rates. These data offer important mechanistic insight into these remarkable machines, and the new strains developed allow for the synthesis of homogeneous chaperonins for biochemical studies and to further our efforts to de-velop chaperonin-targeted antibiotics. © 2021 Sivinski et al.Note
Open access journalISSN
2161-2129PubMed ID
33436430Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1128/mBio.02167-20
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2021 Sivinski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Related articles
- GroEL/ES inhibitors as potential antibiotics.
- Authors: Abdeen S, Salim N, Mammadova N, Summers CM, Frankson R, Ambrose AJ, Anderson GG, Schultz PG, Horwich AL, Chapman E, Johnson SM
- Issue date: 2016 Jul 1
- Bis-sulfonamido-2-phenylbenzoxazoles Validate the GroES/EL Chaperone System as a Viable Antibiotic Target.
- Authors: Godek J, Sivinski J, Watson ER, Lebario F, Xu W, Stevens M, Zerio CJ, Ambrose AJ, Zhu X, Trindl CA, Zhang DD, Johnson SM, Lander GC, Chapman E
- Issue date: 2024 Jul 31
- Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
- Authors: Stevens M, Howe C, Ray AM, Washburn A, Chitre S, Sivinski J, Park Y, Hoang QQ, Chapman E, Johnson SM
- Issue date: 2020 Nov 15
- Allosteric differences dictate GroEL complementation of E. coli.
- Authors: Sivinski J, Ngo D, Zerio CJ, Ambrose AJ, Watson ER, Kaneko LK, Kostelic MM, Stevens M, Ray AM, Park Y, Wu C, Marty MT, Hoang QQ, Zhang DD, Lander GC, Johnson SM, Chapman E
- Issue date: 2022 Mar
- Purification and characterization of Chromatium vinosum GroEL and GroES proteins overexpressed in Escherichia coli cells lacking the endogenous groESL operon.
- Authors: Dionisi HM, Viale AM
- Issue date: 1998 Nov

